Cure My Disease

Don't miss your cure!

 Log in / Sign up

A finger-prick test that could outpace measles outbreaks

NCT ID NCT05860920

Diagnosis Sponsor: Institut Pasteur de Dakar Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early This study
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 02, 2026 · Last updated Sep 03, 2026 · Updated 1 time

Summary

Researchers in Senegal are testing a new rapid diagnostic test for measles that works with a drop of blood from a finger or a swab of oral fluid. The test is designed for use by health workers without lab training, aiming to confirm cases faster during outbreaks. The study will compare the rapid test's results against standard lab methods to measure its accuracy and practicality in real-world settings.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Measles rapid diagnostic test
What this could lead to
If the rapid test proves accurate, health workers in remote areas could confirm measles cases on the spot, speeding up outbreak response and saving lives.
What could go wrong
The test may not match lab accuracy, especially in early or late infections, and field conditions could affect results. This is a single-country study with 254 participants.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

254 people

The number who actually took part.

Started

Aug 2025

Finished

Jun 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients (all ages) presenting to participating health centres with signs and symptoms consistent with being a suspected measles case (WHO definition), for whom diagnostic testing is indicated for laboratory confirmation for national measles and rubella surveillance purposes in Senegal.

Ages

Children (under 18), adults (18 to 64) and older adults (65 and over)

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Patients presenting at study sites: * For whom confirmatory diagnostic testing is currently indicated as per the national surveillance protocol * With clinical signs and symptoms consistent with the WHO suspected measles case definition including: History of fever, or observed fever (\>37.5C) at presentation and a (non-vesicular) maculopapular rash; or clinically suspected measles * ≤ 28 days after the onset of a rash * Who if \<18 years of age, have written, informed consent from their legal guardian (and verbally assent if more than 7 years old) * Who if more than 18 years, give written, informed consent Exclusion Criteria: * Withdrawal of consent or assent as described above, at any time. * Unsuccessful venous blood sampling after a maximum of 3 attempts, or a serum sample is no longer available for any reason. * Clinical signs or symptoms requiring immediate referral/transfer of the patient to another site or centre, and/or for whom participation would involve a delay of urgent clinical interventions or investigations (i.e. potential inclusion of patients requiring immediate clinical management should be deferred until the patient is clinically stable). * Clinical signs or symptoms that may be exacerbated by blood draw or upper respiratory sampling (e.g. stridor or severe respiratory distress) Participants who meet the inclusion criteria should be included in the study but without oral fluid sampling if: * They have a sore mouth or gums that would be exacerbated with oral fluid sampling * They are significantly dehydrated and the mouth is very dry * They refuse or are not able to cooperate with oral fluid sampling

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Measles are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

measles

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Measles

Contacts and locations

Locations

  • Dakar Regional Health Directorate : Dakar Sud Health District: 1 Health Center-Cheikh Ahmadou Bamba and 3 Health Posts-Sandial, Saint Laurent and Service d'Hygiène.

    Dakar, Senegal

  • Dakar Regional Health Directorate :Guédiawaye Health District: 1 Health Centre-Wakhinane Health Centre, 1 Hospital-EPS Roi Baudouin, and 3 Health Posts-Medina Gounass, Nimzatt and Hamo 5

    Guédiawaye, Dakar, Senegal

  • Diourbel Regional Health Directorate : Touba Health District: 6 Health Centers-Darou Khoudouss, Saïdyl Badawi, Keur Niang, Serigne Saliou Mbacké, Darou Marnane, and Darou Tanzil and 3 Health Posts-Lansar, Darou Khadim, and Héliport

    Touba, Diourbel Region, Senegal

  • Kédougou Regional Health Directorate 1 : Kédougou Health District : 2 Health Centers-Kédougou and Ndiormi, 1 Hospital-Amath Dansokho Regional Hospital Center and 1 Health Post-Bantako

    Kedougou, Senegal

  • Kédougou Regional Health Directorate : Saraya Health District: 1 Health Centre-Saraya, 9 Health Posts-Khossanto, Bambaraya, Wassangara, Mourang, Diakhaling, Bembou, Sabadola, Moussala and Sambranbougou

    Saraya, Kedougou, Senegal

  • Tambacounda Regional Health Directorate : Tambacounda Health District : 1 Health Center-Tambacounda Health Centre.

    Tambacounda, Senegal

More trials for these conditions

Other studies related to the condition(s) this trial covers.